BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2020 on Tuesday, April 28, 2020 after the market close.

Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by the resignation of Eric Willis.

Sensor-App-Phone Bundle Expected to Help Expedite Deployment of Remote Patient Management Solution to Patients Without Smartphones

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter financial results on Thursday, May 7, 2020 at 7:00 a.m. ET.

Cutera, Inc. (NASDAQ: CUTR) (“Cutera”), a provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Cutera intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering. All of the shares in the

Profound Medical Corp. will announce its first quarter 2020 financial results after market close on Thursday, May 7, 2020.

Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2020 after the market close on Thursday, May 7, 2020. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at

True Diagnostics, Inc. announced today their Strategic Alliance to develop and commercialize VeraTePrep

Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2020 financial results on May 7, 2020 and members of its senior management team will host a conference call and webcast at 8:00am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./ Canada (866) 497-0462, International (67

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 4,787,553 shares of the Company’s common stock,